CINCINNATI, June 20,
2022 /PRNewswire/ -- Meridian Bioscience, Inc.
(NASDAQ: VIVO), a leading global provider of diagnostic testing
solutions and life science raw materials, announced today two new
sample-specific master mixes, Lyo-Ready™ Direct DNA qPCR Stool
Mix, and Lyo-Ready™ Direct RNA/DNA qPCR Stool Mix. These
innovative master mixes improve the molecular detection of DNA and
RNA from crude fecal specimens while allowing room temperature
stabilization of diagnostic assays.
Stool samples are used in many gastrointestinal diagnostic tests
to screen for harmful bacteria, fungi, viruses, autoimmune
conditions, and colorectal cancer (CRC). The fecal occult blood
test (FOBT) has been the most widely used gastrointestinal
immunoassay to screen CRC for over three decades. However, recent
large-scale studies have shown that the FOBT lacks the sensitivity
to detect early stages of CRC. Better diagnostic tools are needed
to improve assay accuracy, sensitivity, and affordability.
Molecular testing is the newest alternative and offers significant
improvement in sensitivity and accuracy, especially when multiple
targets are detected in the results of a multiplex test. Detection
of DNA or RNA from stool is challenging because it contains an
array of PCR inhibitors including bile salts, polysaccharides, and
catabolic substances. To overcome these challenges, assays
typically require expensive and time-consuming sample processing
and extraction steps which increase the time to results and cost –
ultimately delaying physician diagnosis and patient treatment.
Meridian's new Lyo-Ready™ Direct DNA qPCR Stool and
Lyo-Ready™ Direct RNA/DNA qPCR Stool Mixes remove the need for
time-consuming nucleic acid extraction or lengthy component
optimization. This enables test developers to quickly develop
faster and more sensitive assays for stool sample analysis. In
addition, the mixes can be used in liquid or lyophilized format
when ambient temperature assay stabilization is needed, removing
the need for cold storage.
Florent Chang-Pi-Hin, Ph.D., Vice
President of Research & Development - Life Science, commented,
"The use of Lyo-Ready™ Direct qPCR Stool mixes for DNA and RNA
is ideal for cancer biomarker detection, early cancer detection,
and cancer treatment monitoring where assay sensitivity can be
lifesaving. The specific adaptation of our chemistries to stool
specimens makes our master mixes the perfect tool for any developer
seeking faster new product introduction, shorter time to results,
or the ability to transform a wet assay to an ambient
temperature-stable assay with minimum developmental time."
Meridian is committed to creating innovative solutions that
simplify and accelerate the development of superior diagnostic
assays. For more information on leveraging of
Lyo-Ready™ technology for your assay development, please visit
https://www.meridianbioscience.com/lifescience/products/molecular-reagents/lyo-ready-air-dryable-master-mixes-reagents/
or contact Paul.Marr@meridianlifescience.com.
About Meridian Bioscience, Inc.
Meridian is a fully
integrated life science company that develops, manufactures,
markets, and distributes a broad range of innovative diagnostic
products. We are dedicated to developing and delivering better
solutions that give answers with speed, accuracy, and simplicity
that are redefining the possibilities of life from discovery to
diagnosis. Through discovery and development, we provide critical
life science raw materials used in immunological and molecular
tests for human, animal, plant, and environmental applications.
Through diagnosis, we provide diagnostic solutions in areas
including gastrointestinal and upper respiratory infections and
blood lead level testing. We build relationships and provide
solutions to hospitals, reference laboratories, research centers,
veterinary testing centers, physician offices, diagnostics
manufacturers, and biotech companies in more than 70 countries
around the world.
Meridian's shares are traded on the NASDAQ Global Select Market,
symbol VIVO. Meridian's website address is
www.meridianbioscience.com.
Contact:
Charlie
Wood
Vice President – Investor Relations
Meridian Bioscience, Inc.
Phone: +1 513.271.3700
Email: mbi@meridianbioscience.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/meridian-launches-new-qpcr-master-mixes-for-stool-samples-to-accelerate-development-of-molecular-assays-301570593.html
SOURCE Meridian Bioscience, Inc.